Virios Therapeutics, Inc. (NASDAQ:VIRI - Get Free Report) fell 2.1% during mid-day trading on Monday . The company traded as low as $5.08 and last traded at $5.18. 35,069 shares changed hands during trading, a decline of 97% from the average session volume of 1,049,645 shares. The stock had previously closed at $5.29.
Virios Therapeutics Trading Up 6.3%
The company has a market capitalization of $107.84 million, a PE ratio of -20.74 and a beta of 1.58. The stock has a fifty day simple moving average of $4.80 and a 200-day simple moving average of $5.05.
Virios Therapeutics Company Profile
(
Get Free Report)
Virios Therapeutics, Inc, a development-stage biotechnology company, focuses on developing novel antiviral therapies to treat diseases associated with a viral triggered abnormal immune response. The company's lead development candidate is the IMC-1, a fixed dose combination of famciclovir and celecoxib to treat fibromyalgia.
Recommended Stories
Before you consider Virios Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Virios Therapeutics wasn't on the list.
While Virios Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Explore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
